Insights
Combination Therapies: A Step Forward to the Value Attribution Problem
4 January 2023
OHE convened a roundtable discussion to present and discuss recent work by OHE colleagues and collaborators on value attribution frameworks for combination therapies.
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
Programs to incentivise antibiotic R&D are underway in the UK and under consideration in the US, EU, Canada, and Japan. We have assessed the benefits and costs to the members of the G7/EU and project that all G7/EU members would see big payoffs ranging from 11:1 in the UK to 28:1 for the US and Japan. Global returns from reducing the 1.27m people dying each year from AMR are even higher.
ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”
8 December 2022
OHE, in collaboration with Pfizer, hosted an educational symposium entitled “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA methodologies Appropriately Value and Enable Access?”.
The World Needs New Antibiotics. A Proposed US Program to Develop Them Offers a High Pay-Off
16 November 2022
A Center for Global Development (CGD) paper authored by OHE’s Adrian Towse and CGD’s Rachel Silverman Bonnifield shows a very high expected return on investment (ROI)…
Improving the Measurement of Valued Output in Primary Care in England
1 August 2022
How can we identify efficiency variations across general practices and opportunities to improve their productivity if the measurement of output does not reflect the value produced?
Reforming Primary Health Care in Middle-Income Countries: The Good, the Bad, and the Ugly
18 July 2022
A recent series of papers examines the effects of multiple primary health care interventions (introduction of health facility accreditation, introduction of user fees, and discontinuation of performance-based financing schemes) under Egypt’s Health Sector Reform Program between 2000 and 2014.
The Benefits of Early Engagement with Payers and Patient Representatives: The Case Study of a MoCA Pilot Project on ANCA-associated Vasculitis
30 June 2022
OHE and Vifor Pharma present a poster at the last European Conference on Rare Diseases (ECRD) on the Mechanism of Coordinated Access to orphan medicinal products…
The State of Play for Cost-effectiveness Thresholds
28 June 2022
In a new paper led by OHE, an international team of co-authors considers the evidence for supply-side cost-effectiveness thresholds, providing a set of recommendations for policymakers.…
Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
22 June 2022
Since the Office of Health Economics (OHE) published a critique of CBO’s new simulation model of new drug development late last year, the U.S. public sector think tank has made three improvements to its methodology. We review these updates, assess their impact, and highlight the key remaining limitations of the modelling approach, concluding that policymakers should still exercise considerable caution in relying on its predictions.